



Nasser Semmo

Kontakt

Nasser Semmo

Publikationen (13)

Manuel O, Laager M, Hirzel C, Neofytos D, Walti L, Hönger G, Binet F, Schnyder A, Stampf S, Koller M, Mombelli M, Kim M, Hoffmann M, Koenig K, Hess C, Burgener A, Cippà P, Hübel K, Müller T, Sidler D, Dahdal S, Suter-Riniker F, Villard J, Zbinden A, Pantaleo G, Semmo N, Hadaya K, Enriquez N, Meylan P, Froissart M, Golshayan D, Fehr T, Huynh-Do U, Pascual M, Van Delden C, Hirsch H, Jüni P, Müller N, Swiss Transplant Cohort Study (STCS). Immune monitoring-guided vs fixed duration of antiviral prophylaxis against cytomegalovirus in solid-organ transplant recipients. A Multicenter, Randomized Clinical Trial. *Clin Infect Dis* 2023

Bihl F, Semmo N, Semela D, Scheidegger C, Razavi H, Negro F, Mullhaupt B, Lavanchy D, Dufour J, Castro Batánjer E, Bruggmann P, Blach S. HCV disease burden and population segments in Switzerland. *Liver Int* 2021

Bobzin C, Semmo N, Semela D, Scheidegger C, Rauch A, Negro F, Moradpour D, Mäschi B, Lavanchy D, Künzler-Heule P, Keiser O, Fraga Christinet M, Cerny A, Bruggmann P, Bösisger C, Thurnheer M. Empfehlungen für die Nachsorge von Patientinnen/Patienten mit ausgeheilter Hepatitis C. *Swiss Medical Forum* 2021; 21:184-186.

Mullhaupt B, Semela D, Ruckstuhl L, Magenta L, Clerc O, Torgler R, Negro F, Semmo N. Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. *Swiss Med Wkly* 2021; 151:w20399.

Semmo N, Mullhaupt B, Ruckstuhl L, Magenta L, Clerc O, Torgler R, Semela D. A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving 3D regimen: The HEMATITE study. *PloS one* 2020; 15:e0241267.

Roelens M, Keiser O, Negro F, Junker C, Semela D, Clerc O, Mullhaupt B, Schmid P, Semmo N, Cerny A, Moradpour D, Bertisch B, Swiss Hepatitis C Cohort Study. All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS). *Open Forum Infect Dis* 2020; 7:ofaa308.

About F, Casanova J, Theodorou I, Sultanik P, Poynard T, Pol S, Bochud P, Cobat A, Abel L, Swiss Hepatitis C Cohort Study Group, Semmo N, Semela D, Bibert S, Jouanguy E, Nalpas B, Lorenzo L, Rattina V, Zarhrate M, Hanein S, Munteanu M, Mullhaupt B, French ANRS HC EP 26 Genoscan Study Group. Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation Sequencing. *Front Genet* 2019; 10:1024.

Brezzi M, Keiser O, Negro F, Semela D, Mullhaupt B, Semmo N, Terziroli Beretta-Piccoli B, Moradpour D, Roelens M, Bertisch B, Swiss Hepatitis C Cohort Study. Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study. *PloS one* 2019; 14:e0218706.

Terziroli Beretta-Piccoli B, Muratori L, Vergani D, Mieli-Vergani G, Moradpour D, Semela D, Semmo N, Mertens J, Cerny A, Melidona L, Tesei C, Silvestri T, Grondona A, Deleonardi G, Di Bartolomeo C, Swiss Hepatitis C Cohort Study. Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents. *J Autoimmun* 2019; 102:89-95.

Gauthiez E, Moradpour D, Mullhaupt B, Negro F, Semela D, Semmo N, Villard J, Bibert S, Bochud P, Malinverni R, Heim M, Habfast-Robertson I, Rüeger S, Kutalik Z, Aubert V, Berg T, Cerny A, Gorgievski M, George J, Swiss Hepatitis C Cohort Study. A systematic review and meta-analysis of HCV clearance. *Liver Int* 2017; 37:1431-1445.

Terczyńska-Dyla E, Moradpour D, Mullhaupt B, Negro F, Santoro R, Semela D, Semmo N, Swiss Hepatitis C Cohort Study Group, Heim M, Bochud P, Mangia A, Malinverni R, Bibert S, Duong F, Krol I, Jørgensen S, Collinet E, Kutalik Z, Aubert V, Cerny A, Kaiser L, Hartmann R. Corrigendum: reduced IFN λ 4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. *Nat Commun* 2015; 6:7280.

Terczyńska-Dyla E, Moradpour D, Mullhaupt B, Negro F, Santoro R, Semela D, Semmo N, Swiss Hepatitis C Cohort Study Group, Heim M, Bochud P, Mangia A, Malinverni R, Bibert S, Duong F, Krol I, Jørgensen S, Collinet E, Kutalik Z, Aubert V, Cerny A, Kaiser L, Hartmann R. Reduced IFN λ 4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. *Nat Commun* 2014; 5:5699.

Lucas M, Santantonio T, Fidler S, Thimme R, Haberstroh A, Baumert T, Klenerman P, Diepolder H, Nitschko H, Obermeier M, Phillips R, Scriba T, Semmo N, Day C, Weber J, Schraut W, Pape G, Zachoval R, Ulsenheimer A, Pfafferot K, Heeg M, Gaudieri S, Grüner N, Rauch A, Gerlach T, Jung M. Tracking virus-specific CD4⁺ T cells during and after acute hepatitis C virus infection. *PloS one* 2007; 2:e649.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch